Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | USP5 | P45974 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449524 | 0.76 | CCR1 (0.33) | — | |
| SCHEMBL6015115 | 0.75 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1F10ALDH1A1CHRM1 | |
| SCHEMBL3448782 | 0.73 | VNN1 (0.41) | F10KCNH2 | |
| SCHEMBL3449578 | 0.73 | F10 (0.41) | F10 | |
| SCHEMBL3450076 | 0.72 | VNN1 (0.42) | F10CHRM1 | |
| SCHEMBL4685372 | 0.71 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1F10ALDH1A1 | |
| SCHEMBL6600988 | 0.71 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1F10ALDH1A1 | |
| SCHEMBL1464487 | 0.70 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1ALDH1A1KCNH2HRH3 | |
| SCHEMBL28730371 | 0.70 | HSD17B10 (0.41) | ALDH1A1CHRM1CHRM3KDM4ETSHR | |
| SCHEMBL28730369 | 0.70 | HSD17B10 (0.41) | ALDH1A1CHRM1CHRM3KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | L3MBTL3 4413/4885L3MBTL1 4401/4885F10 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.